Monitoring methicillin-resistant Staphylococcus aureus prevalence in Taiwan: a hospital-based surveillance study from 2022 to 2024

IF 1.7 Q4 INFECTIOUS DISEASES

IJID regions Pub Date : 2025-07-10 DOI:10.1016/j.ijregi.2025.100702

Ying-Ju Chen , Tze-Kiong Er

{"title":"Monitoring methicillin-resistant Staphylococcus aureus prevalence in Taiwan: a hospital-based surveillance study from 2022 to 2024","authors":"Ying-Ju Chen , Tze-Kiong Er","doi":"10.1016/j.ijregi.2025.100702","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) remains a significant public health concern, associated with high morbidity, increased healthcare costs, and limited treatment options due to antimicrobial resistance. Monitoring MRSA trends is essential to support effective infection prevention and control strategies in healthcare settings.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed clinical specimens tested for <em>Staphylococcus aureus</em> between January 2022 and December 2024 at a regional hospital in central Taiwan. Monthly and annual MRSA prevalence rates were calculated as the proportion of MRSA-positive isolates. A chi-square test of independence was used to assess the statistical significance of prevalence differences across years.</div></div><div><h3>Results</h3><div>A total of 1,824 <em>Staphylococcus aureus</em> isolates were identified during the study period, including 287 MRSA cases in 2022 (48.9%), 281 in 2023 (42.3%), and 278 in 2024 (48.5%). The chi-square test revealed a statistically significant difference in annual MRSA prevalence (χ² = 6.94, <em>P</em> = 0.031), indicating a meaningful variation in resistance patterns across years.</div></div><div><h3>Conclusion</h3><div>MRSA prevalence fluctuated over the 3-year period, with a temporary decline in 2023 followed by a rebound in 2024. These findings underscore the importance of continuous surveillance and adaptable infection control strategies to address evolving antimicrobial resistance in hospital environments.</div></div>","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"16 ","pages":"Article 100702"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJID regions","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772707625001377","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Methicillin-resistant Staphylococcus aureus (MRSA) remains a significant public health concern, associated with high morbidity, increased healthcare costs, and limited treatment options due to antimicrobial resistance. Monitoring MRSA trends is essential to support effective infection prevention and control strategies in healthcare settings.

Methods

This retrospective study analyzed clinical specimens tested for Staphylococcus aureus between January 2022 and December 2024 at a regional hospital in central Taiwan. Monthly and annual MRSA prevalence rates were calculated as the proportion of MRSA-positive isolates. A chi-square test of independence was used to assess the statistical significance of prevalence differences across years.

Results

A total of 1,824 Staphylococcus aureus isolates were identified during the study period, including 287 MRSA cases in 2022 (48.9%), 281 in 2023 (42.3%), and 278 in 2024 (48.5%). The chi-square test revealed a statistically significant difference in annual MRSA prevalence (χ² = 6.94, P = 0.031), indicating a meaningful variation in resistance patterns across years.

Conclusion

MRSA prevalence fluctuated over the 3-year period, with a temporary decline in 2023 followed by a rebound in 2024. These findings underscore the importance of continuous surveillance and adaptable infection control strategies to address evolving antimicrobial resistance in hospital environments.

查看原文本刊更多论文

台湾耐甲氧西林金黄色葡萄球菌流行监测：2022 - 2024年医院监测研究

目的耐甲氧西林金黄色葡萄球菌（MRSA）仍然是一个重要的公共卫生问题，与高发病率、增加的医疗费用和有限的治疗选择有关。监测耐甲氧西林金黄色葡萄球菌趋势对于支持卫生保健机构有效的感染预防和控制战略至关重要。方法回顾性分析台湾中部某地区医院2022年1月至2024年12月的临床金黄色葡萄球菌检测标本。每月和每年MRSA流行率计算为MRSA阳性分离株的比例。采用卡方独立性检验评估各年患病率差异的统计学意义。结果研究期间共检出金黄色葡萄球菌1824株，其中2022年MRSA 287例（48.9%），2023年281例（42.3%），2024年278例（48.5%）。卡方检验显示，MRSA年患病率差异有统计学意义（χ²= 6.94,P = 0.031），表明耐药模式在各年之间存在显著差异。结论mrsa患病率呈波动趋势，2023年出现暂时下降，2024年出现反弹。这些发现强调了持续监测和适应性感染控制策略的重要性，以解决医院环境中不断变化的抗菌素耐药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊